News Image

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Provided By GlobeNewswire

Last update: Jun 9, 2025

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe

Read more at globenewswire.com

PDS BIOTECHNOLOGY CORP

NASDAQ:PDSB (10/23/2025, 1:28:45 PM)

0.9

-0.03 (-3.23%)



Find more stocks in the Stock Screener

Follow ChartMill for more